louisiana glp-1 constipation lawyer Ozempic Lawsuit [July 2026 Update] As weight loss drugs like

A recent paper published in JAMA Ophthalmology found a possible link between liraglutide and a higher incidence of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in adults with diabetes

What is already known on this topic Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors reduce the risk of cardiovascular and renal events in patients with type 2 diabetes These drug classes are increasingly used in combination when previous therapy with other antihyperglycaemic drugs fails Whether the combined use of these drug classes results in improved cardiovascular and renal outcomes in the real world setting, compared with the use of either drug class alone, remains unclear What this study adds This population based cohort study aimed at emulating a randomised controlled trial The combined use of a GLP-1 receptor agonist and an SGLT-2 inhibitor was associated with a lower risk of cardiovascular and serious renal events, compared with either drug class alone These findings highlight the potential benefit of combining these two effective drug classes in preventing cardiovascular and renal events in the treatment of type 2 diabetes Data availability statement This study is based on data from the Clinical Practice Research Datalink obtained under license from the UK Medicines and Healthcare products Regulatory Agency

Brain-derived neurotrophic factor induces rapid and transient release of glutamate through the non-exocytotic pathway from cortical neurons

Blood samples for measuring 4 h fasting blood glucose were collected at treatment day -1, 8, 16, 22, and 27

But how effective are theyand what does the research say

What Diet and Lifestyle Changes are Necessary on a GLP-1